The treatment of critical size bone defects represents a challenge. The growth factor bone morphogenetic protein 2 (BMP-2) is clinically established but has potentially adverse effects when used at high doses. The aim of this study was to evaluate if stromal derived factor-1 alpha (SDF-1a) and BMP-2 released from heparinized mineralized collagen type I matrix (MCM) scaffolds have a cumulative effect on bone regeneration. MCM scaffolds were functionalized with heparin, loaded with BMP-2 and/or SDF-1a and implanted into a murine critical size femoral bone defect (control group, low dose BMP-2 group, low dose BMP-2?+?SDF-1a group, and high dose BMP-2 group). After 6 weeks, both the low dose BMP-2?+?SDF-1a group (5.8?±?0.6 mm³, p?=?0.0479) and the high dose BMP-2 group (6.5?±?0.7 mm³, p?=?0.008) had a significantly increased regenerated bone volume compared to the control group (4.2?±?0.5 mm³). There was a higher healing score in the low dose BMP-2?+?SDF-1a group (median grade 8; Q1-Q3 7-9; p?=?0.0357) than in the low dose BMP-2 group (7; Q1-Q3 5-9) histologically. This study showed that release of BMP-2 and SDF-1a from heparinized MCM scaffolds allows for the reduction of the applied BMP-2 concentration since SDF-1a seems to enhance the osteoinductive potential of BMP-2. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 2126-2134, 2016.
View details for DOI 10.1002/jbm.a.35744
View details for PubMedID 27060915